On January 12, 2026 Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, aiming to change lives by changing the course of blood cancer, reported 2026 financial guidance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our priorities for 2026 are clear – driving RYTELO commercial growth in the U.S., pursuing paths to bring RYTELO to LR-MDS markets outside the U.S., and advancing our Phase 3 IMpactMF trial," said Harout Semerjian, President and Chief Executive Officer of Geron. "These priorities are supported by a focused commercial strategy, an expanding body of RYTELO scientific evidence and real-world experience, and a streamlined and energized Geron team. Together, these strengths are designed to drive deeper engagement across the hematology community and reinforce our conviction that we can deliver for eligible LR-MDS patients and build Geron into a leading, sustainable hematology company."

"Our 2026 financial guidance reflects expected top-line growth alongside an anticipated reduction in operating spend year over year, reinforcing the strength of our balance sheet," said Michelle Robertson, Chief Financial Officer. "We expect RYTELO net revenue growth to be driven by more focused HCP and patient targeting, with stronger performance in the second half of the year. Our anticipated 2026 total operating expense base reflects our recent strategic restructuring and is expected to support continued investment in RYTELO commercial strategy and clinical development priorities."

2026 Financial Guidance

RYTELO net product revenue expected in the range of $220 million to $240 million.
Total operating expenses expected in the range of $230 million to $240 million.

Business Highlights

Expanded the scientific body of evidence supporting the potential of RYTELO (imetelsat), a first-in-class telomerase inhibitor, in lower-risk myelodysplastic syndromes/Neoplasms (LR-MDS) at the 2025 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, with an oral and poster presentations of new analyses from the Phase 3 IMerge trial reinforcing RYTELO as a differentiated treatment option.
Implemented a strategic restructuring plan, from a position of strength, designed to streamline the Company and support the RYTELO commercial strategy and opportunistic innovation to create long-term value for patients and shareholders.
Announced a first amendment to the existing 5-year senior secured term loan facility agreement with investment funds managed by Pharmakon Advisors, LP to extend the outside date for requesting the Tranche B Loan (an aggregate principal amount of $75 million) and the Tranche C Loan (an aggregate principal amount of $50 million, available upon reaching a specified trailing twelve-month RYTELO revenue milestone), from December 31, 2025 to July 30, 2026.

About RYTELO (imetelstat)
RYTELO is an oligonucleotide telomerase inhibitor approved in the U.S. for the treatment of adult patients with LR-MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks.

In addition, RYTELO is approved in the European Union as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission.

(Press release, Geron, JAN 12, 2026, View Source [SID1234661952])